Wire · opportunities
Experimental treatment may preserve upper limb function in DMD
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 October 2026 · Fusion42 review
Clinical trial data shows that deramiocel, an experimental cell therapy from Capricor Therapeutics, may slow decline in upper limb function in boys and young men with Duchenne muscular dystrophy (DMD). A U.S. FDA decision on approval is expected by November 22, 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can target a high-impact but underserved aspect of Duchenne muscular dystrophy—upper limb function—with new cell therapy data unlocking potential market access as FDA decision looms. Prepare for an entry point that centres on independence and quality of life improvements.
◆ Coverage
1 source · 8 Oct 2026
◆ Related on Wire
◆ Topics